Hemispherx BioPharma, Inc Share Price Nyse
Equities
US42366C1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 113K 9.46M | Sales 2025 * | 1.78M 149M | Capitalization | 19.96M 1.67B |
---|---|---|---|---|---|
Net income 2024 * | -24M -2B | Net income 2025 * | -25M -2.09B | EV / Sales 2024 * | 176 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-0.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 04/22/04 |
Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 28/23/28 |
William Mitchell
CHM | Chairman | 89 | 01/98/01 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |